Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 2.109
Filtrar
2.
AAPS PharmSciTech ; 22(3): 77, 2021 Feb 17.
Artículo en Inglés | MEDLINE | ID: mdl-33595740

RESUMEN

Currently, periodontitis is treated by oral dosage forms (antibiotics) which shows systemic side effects and failed to reach the therapeutic concentration (above minimum inhibitory concentration, MIC) in the periodontal pocket. The present study aimed to overcome the above issues, by designing tailored doxycycline hyclate laden in situ gel by Poloxamer 407, chitosan, and polyethylene glycol 600. The in situ gel-forming system has attracted attention owing to its ability of sustained drug release above MIC, easy administration (syringeability), and high drug retention (localization) in the periodontal cavity. The Box-Behnken design (BBD) was used to tailor and optimize the concentration of Poloxamer 407 (X1 = 14.3%), chitosan (X2 = 0.58%), and polyethylene glycol 600 (X3 = 1.14%) to achieve sufficient syringeability (149 N), t90% (1105 min), and viscosity at non-physiological condition (512 cps) and physiological condition (5415 cps). The optimized in situ gel was clear and isotonic (RBCs test). The gelation temperature of the optimized in situ was 34 ± 1°C with sufficient mucoadhesive strength (26 ± 2 dyn/cm2), gel strength (29 ± 2 sec), and texture profile for periodontal application. The in vitro drug release studies showed sustain release from optimized in situ gel (24h) in comparison to marketed gel (7h). The antimicrobial activity (cup plate technique) of the in situ gel was equivalent to the marketed doxycycline gel, which suggests that the doxycycline hyclate retained its antimicrobial efficacy when formulated as in situ gelling system. In conclusion, BBD was effectively utilized to optimize in situ gel with minimum level of polymers to achieve the required characteristics of the in situ gel for sustaining drug delivery to treat periodontitis.


Asunto(s)
Antibacterianos/administración & dosificación , Doxiciclina/administración & dosificación , Sistemas de Liberación de Medicamentos , Periodontitis/tratamiento farmacológico , Quitosano/química , Doxiciclina/química , Sistemas de Liberación de Medicamentos/métodos , Liberación de Fármacos , Geles/administración & dosificación , Humanos , Poloxámero/química , Polímeros/química
3.
ACS Appl Mater Interfaces ; 13(2): 2371-2381, 2021 Jan 20.
Artículo en Inglés | MEDLINE | ID: mdl-33404209

RESUMEN

This work describes the preparation and characterization of printed biodegradable polymer (polylactic acid) capsules made in two different shapes: pyramid and rectangular capsules about 1 and 11 µm in size. Obtained core-shell capsules are described in terms of their morphology, loading efficiency, cargo release profile, cell cytotoxicity, and cell uptake. Both types of capsules showed monodisperse size and shape distribution and were found to provide sufficient stability to encapsulate small water-soluble molecules and to retain them for several days and ability for intracellular delivery. Capsules of 1 µm size can be internalized by HeLa cells without causing any toxicity effect. Printed capsules show unique characteristics compared with other drug delivery systems such as a wide range of possible cargoes, triggered release mechanism, and highly controllable shape and size.


Asunto(s)
Composición de Medicamentos/métodos , Sistemas de Liberación de Medicamentos , Poliésteres/química , Animales , Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Cápsulas/química , Línea Celular , Doxiciclina/administración & dosificación , Doxiciclina/farmacocinética , Composición de Medicamentos/instrumentación , Diseño de Equipo , Células HeLa , Humanos , Ratones , Tamaño de la Partícula , Impresión Tridimensional/instrumentación
4.
BMJ Case Rep ; 14(1)2021 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-33462032

RESUMEN

Morel-Lavallée lesion is a chronic, recurrent collection of serous fluid in the soft tissues and usually occurs following injury. The most common sites are thigh, hip and pelvic region. This presents as a local or diffuse swelling and may cause discomfort to the patient besides being a potential site for bacterial contamination. So, early diagnosis and timely management is crucial for an early and successful outcome. The investigation modality of choice for diagnosis of these lesions is MRI. Definitive management ranges from percutaneous aspiration with or without sclerotherapy to open debridement and irrigation. Although recurrences are common with conservative management, it can be minimised with judicious use of sclerotherapy.


Asunto(s)
Antibacterianos/administración & dosificación , Doxiciclina/administración & dosificación , Escleroterapia , Seroma/diagnóstico , Seroma/etiología , Muslo/lesiones , Accidentes por Caídas , Desbridamiento , Drenaje , Femenino , Humanos , Seroma/terapia , Adulto Joven
5.
Av. odontoestomatol ; 36(3): 161-173, sept.-dic. 2020. graf
Artículo en Español | IBECS | ID: ibc-197415

RESUMEN

INTRODUCCIÓN: la sífilis es una infección bacteriana, que se puede transmitir por contacto sexual o de forma congénita. Esta enfermedad consta de tres estadios, en los cuales se pueden dar diferentes manifestaciones orales. MATERIAL Y MÉTODO: se realizó una búsqueda en la base de datos PubMed, utilizándose como palabras clave: "sexually transmitted diseases", "venereal diseases", "syphilis", "primary syphilis", "secondary syphilis", "tertiary syphilis", "oral manifestations", "oral lesions". Como criterios de inclusión se emplearon: series de casos, estudios en los que el tema principal fueran las manifestaciones orales de la sífilis y trabajos en inglés y español. No hubo restricción por fecha. RESULTADOS: se seleccionaron un total de 18 artículos, la N total de pacientes fue de 201. El 10,05% padecía sífilis primaria, el 52,76% sífilis secundaria y el 36, 68% sífilis terciaria. Las lesiones orales predominantes de la sífilis primaria fueron úlceras, inflamación, chancro sifilítico; en la sífilis secundaria se apreciaban placas mucosas, lesiones eritematosas, inflamación, lesiones papulares, lesiones maculares, lesiones erosivas; en la sífilis terciaria aparecen gomas sifilíticos, lesiones leucoplásicas y atrofia lingual. DISCUSIÓN: la sífilis es una infección bacteriana que puede simular diversas enfermedades, es muy importante tenerla en cuenta a la hora de realizar el diagnóstico diferencial de diversas lesiones orales, sobre todo aquellas que se presentan de forma ulcerosa, indurada y asintomática


INTRODUCTION: syphilis is a bacterial infection, which is transmitted by sexual contact or congenitally. This disease develops in three stages, in which different oral manifestations can occur. MATERIAL AND METHOD: a search was made in the PubMed database, using as keywords: "sexually transmitted diseases", "venereal diseases", "syphilis", "primary syphilis", "secondary syphilis", "tertiary syphilis", "Oral manifestations", "oral lesions". The inclusion criteria were: case series, studies in which the main theme was the oral manifestations of syphilis and works in English and Spanish. There was no restriction by date. RESULTS: a total of 18 articles were selected, the total sample of patients was 201. 10.05% had primary syphilis, 52.76% secondary syphilis and 36, 68% tertiary syphilis. The predominant oral lesions of primary syphilis were ulcers, inflammation, syphilitic chancre; in secondary syphilis there were mucous patches, erythematous lesions, inflammation, papular lesions, macular lesions, erosive lesions; in tertiary syphilis, syphilitic gums, leukoplastic lesions and lingual atrophy. DISCUSSION: Syphilis is a bacterial infection that can simulate various diseases, it is very important to take it into account when making the differential diagnosis of various oral lesions, especially those that occur in an ulcerative, indurated and asymptomatic form


Asunto(s)
Humanos , Sífilis/patología , Sífilis/epidemiología , Enfermedades de la Boca/patología , Sífilis/diagnóstico , Boca/lesiones , Diagnóstico Diferencial , Penicilinas/administración & dosificación , Penicilina G Benzatina/administración & dosificación , Doxiciclina/administración & dosificación , Amoxicilina/administración & dosificación , Probenecid/administración & dosificación
6.
MMWR Morb Mortal Wkly Rep ; 69(50): 1911-1916, 2020 Dec 18.
Artículo en Inglés | MEDLINE | ID: mdl-33332296

RESUMEN

Sexually transmitted infections (STIs) caused by the bacteria Neisseria gonorrhoeae (gonococcal infections) have increased 63% since 2014 and are a cause of sequelae including pelvic inflammatory disease, ectopic pregnancy, and infertility and can facilitate transmission of human immunodeficiency virus (HIV) (1,2). Effective treatment can prevent complications and transmission, but N. gonorrhoeae's ability to acquire antimicrobial resistance influences treatment recommendations and complicates control (3). In 2010, CDC recommended a single 250 mg intramuscular (IM) dose of ceftriaxone and a single 1 g oral dose of azithromycin for treatment of uncomplicated gonococcal infections of the cervix, urethra, and rectum as a strategy for preventing ceftriaxone resistance and treating possible coinfection with Chlamydia trachomatis (4). Increasing concern for antimicrobial stewardship and the potential impact of dual therapy on commensal organisms and concurrent pathogens (3), in conjunction with the continued low incidence of ceftriaxone resistance and the increased incidence of azithromycin resistance, has led to reevaluation of this recommendation. This report, which updates previous guidelines (5), recommends a single 500 mg IM dose of ceftriaxone for treatment of uncomplicated urogenital, anorectal, and pharyngeal gonorrhea. If chlamydial infection has not been excluded, concurrent treatment with doxycycline (100 mg orally twice a day for 7 days) is recommended. Continuing to monitor for emergence of ceftriaxone resistance through surveillance and health care providers' reporting of treatment failures is essential to ensuring continued efficacy of recommended regimens.


Asunto(s)
Gonorrea/tratamiento farmacológico , Guías de Práctica Clínica como Asunto , Administración Oral , Ceftriaxona/administración & dosificación , Centers for Disease Control and Prevention, U.S. , Infecciones por Chlamydia/complicaciones , Infecciones por Chlamydia/tratamiento farmacológico , Chlamydia trachomatis , Coinfección/tratamiento farmacológico , Doxiciclina/administración & dosificación , Medicina Basada en la Evidencia , Gonorrea/complicaciones , Humanos , Inyecciones Intramusculares , Estados Unidos
7.
Korean J Parasitol ; 58(5): 565-569, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-33202509

RESUMEN

This report describes the first clinical case of a transfusion-associated Mycoplasma haemocanis infection in a dog in Korea. A 6-year-old male Maltese underwent a red blood cell transfusion for idiopathic immune-mediated hemolytic anemia. Eighteen days after the blood transfusion, the recipient's packed cell volume decreased and basophilic organisms were found on erythrocytes. A polymerase chain reaction and sequential analysis showed that both the donor dog and recipient dog had M. haemocanis. Six weeks after doxycycline administration, no organisms were detected and the recipient's anemia had improved.


Asunto(s)
Anemia Hemolítica Autoinmune/terapia , Anemia Hemolítica Autoinmune/veterinaria , Transfusión Sanguínea/veterinaria , Enfermedades de los Perros/terapia , Enfermedades de los Perros/transmisión , Doxiciclina/administración & dosificación , Infecciones por Mycoplasma/transmisión , Infecciones por Mycoplasma/veterinaria , Mycoplasma , Reacción a la Transfusión/microbiología , Reacción a la Transfusión/veterinaria , Animales , Enfermedades de los Perros/etiología , Enfermedades de los Perros/microbiología , Perros , Masculino , Infecciones por Mycoplasma/tratamiento farmacológico , Infecciones por Mycoplasma/microbiología , República de Corea , Resultado del Tratamiento
8.
BMC Infect Dis ; 20(1): 826, 2020 Nov 11.
Artículo en Inglés | MEDLINE | ID: mdl-33176719

RESUMEN

BACKGROUND: Human granulocytic anaplasmosis (HGA) is a tick-borne infectious disease caused by Anaplasma phagocytophilum. To date, there have been no reported cases of A. phagocytophilum infection found in both the biting tick and the patient following a tick bite. CASE PRESENTATION: An 81-year-old woman presented with fever following a tick bite, with the tick still intact on her body. The patient was diagnosed with HGA. The tick was identified as Ixodes nipponensis by morphological and molecular biological detection methods targeting the 16S rRNA gene. The patient's blood was cultured after inoculation into the human promyelocytic leukemia cell line HL-60. A. phagocytophilum growth was confirmed via culture and isolation. A. phagocytophilum was identified in both the tick and the patient's blood by Anaplasma-specific groEL- and ankA-based nested polymerase chain reaction followed by sequencing. Moreover, a four-fold elevation in antibodies was observed in the patient's blood. CONCLUSION: We report a case of a patient diagnosed with HGA following admission for fever due to a tick bite. A. phagocytophilum was identified in both the tick and the patient, and A. phagocytophilum was successfully cultured. The present study suggests the need to investigate the possible incrimination of I. nipponensis as a vector for HGA in Korea.


Asunto(s)
Anaplasma phagocytophilum/genética , Anaplasmosis/diagnóstico , Ixodes/microbiología , Mordeduras de Garrapatas/microbiología , Enfermedades por Picaduras de Garrapatas/diagnóstico , Anciano de 80 o más Años , Anaplasma phagocytophilum/aislamiento & purificación , Anaplasmosis/tratamiento farmacológico , Anaplasmosis/microbiología , Animales , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Doxiciclina/administración & dosificación , Doxiciclina/uso terapéutico , Femenino , Fiebre , Células HL-60 , Humanos , Reacción en Cadena de la Polimerasa , ARN Ribosómico 16S/genética , República de Corea , Enfermedades por Picaduras de Garrapatas/tratamiento farmacológico , Enfermedades por Picaduras de Garrapatas/microbiología , Resultado del Tratamiento
9.
BMJ Case Rep ; 13(11)2020 Nov 03.
Artículo en Inglés | MEDLINE | ID: mdl-33148588

RESUMEN

Fever is a widely recognised presenting symptom of COVID-19. Consequently, other febrile illnesses may be difficult to distinguish from COVID-19-leading to delays in diagnosis and treatment. One such illness is murine typhus, a fleaborne illness with worldwide distribution caused by Rickettsia typhi It often presents with fever, headache and myalgia, all of which have been commonly reported with COVID-19. Although the disease is usually mild with a good prognosis, there have been reports of severe illness and death. I present a case of murine typhus in a young male who had 2 weeks of headaches and daily fevers during the COVID-19 pandemic. He was ultimately tested for murine typhus when his occupation as a dog trainer was queried, and he experienced resolution of symptoms after treatment with doxycycline. During this pandemic, clinicians must be vigilant of other febrile illnesses whose symptoms overlap with COVID-19.


Asunto(s)
Infecciones por Coronavirus/diagnóstico , Doxiciclina/administración & dosificación , Fiebre/diagnóstico , Exposición Profesional/análisis , Neumonía Viral/diagnóstico , Rickettsia typhi/aislamiento & purificación , Tifus Endémico Transmitido por Pulgas , Adulto , Atención Ambulatoria/métodos , Animales , Antibacterianos/administración & dosificación , Betacoronavirus , Diagnóstico Diferencial , Reservorios de Enfermedades/microbiología , Transmisión de Enfermedad Infecciosa , Perros , Fiebre/etiología , Humanos , Masculino , Pandemias , Resultado del Tratamiento , Tifus Endémico Transmitido por Pulgas/diagnóstico , Tifus Endémico Transmitido por Pulgas/tratamiento farmacológico , Tifus Endémico Transmitido por Pulgas/microbiología , Tifus Endémico Transmitido por Pulgas/fisiopatología
10.
Ther Adv Respir Dis ; 14: 1753466620951053, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32873175

RESUMEN

Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients with pulmonary compromise, such as lung cancer, autoimmune disease, and pneumonia. For early stages of mild to moderate disease, care is entirely supportive.Antiviral drugs such as remdesivir may be of some benefit but are reserved for severe cases given limited availability and potential toxicity. Repurposing of safer, established medications that may have antiviral activity is a possible approach for treatment of earlier-stage disease. Tetracycline and its derivatives (e.g. doxycycline and minocycline) are nontraditional antibiotics with a well-established safety profile, potential efficacy against viral pathogens such as dengue fever and chikungunya, and may regulate pathways important in initial infection, replication, and systemic response to SARS-CoV-2. We present a series of four high-risk, symptomatic, COVID-19+ patients, with known pulmonary disease, treated with doxycycline with subsequent rapid clinical improvement. No safety issues were noted with use of doxycycline.Doxycycline is an attractive candidate as a repurposed drug in the treatment of COVID-19 infection, with an established safety profile, strong preclinical rationale, and compelling initial clinical experience described here.The reviews of this paper are available via the supplemental material section.


Asunto(s)
Adenocarcinoma del Pulmón/complicaciones , Infecciones por Coronavirus/tratamiento farmacológico , Doxiciclina/administración & dosificación , Neumonía Viral/tratamiento farmacológico , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Sarcoidosis Pulmonar/complicaciones , Adenocarcinoma del Pulmón/diagnóstico , Adenocarcinoma del Pulmón/terapia , Adulto , Anciano , Anciano de 80 o más Años , Comorbilidad , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/diagnóstico , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Multimorbilidad , Pandemias , Neumonía Viral/complicaciones , Neumonía Viral/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/terapia , Medición de Riesgo , Muestreo , Sarcoidosis Pulmonar/diagnóstico , Sarcoidosis Pulmonar/terapia , Resultado del Tratamiento
12.
BMC Infect Dis ; 20(1): 505, 2020 Jul 13.
Artículo en Inglés | MEDLINE | ID: mdl-32660552

RESUMEN

BACKGROUND: Meningococcal meningitis (MM) is a life-threatening disease associated with approximately 10% case fatality rates and neurological sequelae in 10-20% of the cases. Recently, we have shown that the matrix metalloproteinase (MMP) inhibitor BB-94 reduced brain injury in a mouse model of MM. The present study aimed to assess whether doxycycline (DOX), a tetracycline that showed a neuroprotective effect as adjuvant therapy in experimental pneumococcal meningitis (PM), would also exert a beneficial effect when given as adjunctive therapy to ceftriaxone (CRO) in experimental MM. METHODS: BALB/c mice were infected by the intracisternal route with a group C Neisseria meningitidis strain. Eighteen h post infection (hpi), animals were randomised for treatment with CRO [100 mg/kg subcutaneously (s.c.)], CRO plus DOX (30 mg/kg s.c.) or saline (control s.c.). Antibiotic treatment was repeated 24 and 40 hpi. Mouse survival and clinical signs, bacterial counts in cerebella, brain damage, MMP-9 and cyto/chemokine levels were assessed 48 hpi. RESULTS: Analysis of bacterial load in cerebella indicated that CRO and CRO + DOX were equally effective at controlling meningococcal replication. No differences in survival were observed between mice treated with CRO (94.4%) or CRO + DOX (95.5%), (p > 0.05). Treatment with CRO + DOX significantly diminished both the number of cerebral hemorrhages (p = 0.029) and the amount of MMP-9 in the brain (p = 0.046) compared to untreated controls, but not to CRO-treated animals (p > 0.05). Levels of inflammatory markers in the brain of mice that received CRO or CRO + DOX were not significantly different (p > 0.05). Overall, there were no significant differences in the parameters assessed between the groups treated with CRO alone or CRO + DOX. CONCLUSIONS: Treatment with CRO + DOX showed similar bactericidal activity to CRO in vivo, suggesting no antagonist effect of DOX on CRO. Combined therapy significantly improved mouse survival and disease severity compared to untreated animals, but addition of DOX to CRO did not offer significant benefits over CRO monotherapy. In contrast to experimental PM, DOX has no adjunctive activity in experimental MM.


Asunto(s)
Antibacterianos/uso terapéutico , Ceftriaxona/uso terapéutico , Doxiciclina/uso terapéutico , Meningitis Meningocócica/tratamiento farmacológico , Neisseria meningitidis Serogrupo C , Animales , Antibacterianos/administración & dosificación , Carga Bacteriana/efectos de los fármacos , Ceftriaxona/administración & dosificación , Hemorragia Cerebral/tratamiento farmacológico , Quimiocinas/análisis , Quimiocinas/metabolismo , Modelos Animales de Enfermedad , Doxiciclina/administración & dosificación , Quimioterapia Combinada , Femenino , Humanos , Estimación de Kaplan-Meier , Metaloproteinasa 9 de la Matriz/análisis , Metaloproteinasa 9 de la Matriz/metabolismo , Meningitis Meningocócica/mortalidad , Ratones , Ratones Endogámicos BALB C , Distribución Aleatoria , Resultado del Tratamiento
16.
Carbohydr Polym ; 237: 116163, 2020 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-32241426

RESUMEN

A polyelectrolyte complex nanoparticle comprising chitosan (CS) and carboxymethyl chitosan (CMCS) was prepared (CS/CMCS-NPs) by ionic gelation, which was then used as a doxycycline carrier (Dox:CS/CMCS-NPs). The obtained CS/CMCS-NPs and Dox:CS/CMCS-NPs were characterized for various parameters and bacteriostatic ability against Porphyromonas gingivalis. The regulation of related genes and proteins of NLRP3 inflammasome and IL-1ß in human gingival fibroblasts (HGFs) was characterized by qRT-PCR, western blotting and ELISA. The results showed that Dox:CS/CMCS-NPs had an orderly morphology and an excellent cytocompatibility. P. gingivalis was strongly inhibited by Dox:CS/CMCS-NPs contrasted with control group. Dox:CS/CMCS-NPs effectively down-regulated both gene and protein levels of NLRP3 inflammasome and IL-1ß in HGFs. This study provides a new method for rational application of Dox in the clinical treatment of periodontal disease and a new direction for explaining the mechanism of action of Dox:CS/CMCS-NPs and more drug-carrying nanoparticles.


Asunto(s)
Antibacterianos/administración & dosificación , Quitosano/análogos & derivados , Doxiciclina/administración & dosificación , Inflamasomas/metabolismo , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Nanopartículas/administración & dosificación , Enfermedades Periodontales/metabolismo , Adolescente , Antibacterianos/química , Células Cultivadas , Quitosano/administración & dosificación , Quitosano/química , Doxiciclina/química , Fibroblastos/efectos de los fármacos , Fibroblastos/metabolismo , Humanos , Inflamasomas/genética , Proteína con Dominio Pirina 3 de la Familia NLR/genética , Nanopartículas/química , Enfermedades Periodontales/genética , Porphyromonas gingivalis/efectos de los fármacos , Porphyromonas gingivalis/crecimiento & desarrollo
17.
Am J Otolaryngol ; 41(4): 102463, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32229044

RESUMEN

Treatment of thoracic duct leaks can be very challenging. Intractable chlye leaks may require image-guided methods to increase the likelihood of treatment success. Near infra-red fluorescence is an easy-to-use nonionizing imaging method that has been described to detect thoracic duct leaks in open surgery or thoracoscopic interventions, yet no application to percutaneous sclerotherapy has been described. The authors suggest near infra-red fluorescence as a feasible and useful tool to guide percutaneous sclerotherapy.


Asunto(s)
Quilotórax/etiología , Quilotórax/terapia , Imagen Óptica/métodos , Complicaciones Posoperatorias/terapia , Escleroterapia/métodos , Conducto Torácico/lesiones , Anciano , Quilotórax/diagnóstico por imagen , Doxiciclina/administración & dosificación , Humanos , Masculino , Soluciones Esclerosantes/administración & dosificación , Resultado del Tratamiento
18.
Arq. bras. oftalmol ; 83(2): 109-112, Mar.-Apr. 2020. tab
Artículo en Inglés | LILACS | ID: biblio-1088962

RESUMEN

ABSTRACT Purpose: To compare the impact of ocular changes between systemic treatment with doxycycline and low-dose oral isotretinoin in patients with moderate-to-severe papulopustular rosacea. Methods: Patients were randomized to receive either isotretinoin 0.3-0.4 mg/kg (group A) or doxycycline 100 mg/day (group B) for 16 weeks. Ocular symptoms were searched and evaluated, including best-corrected visual acuity (BCVA), Schirmer test, breakup time, rose bengal staining score, and meibomian gland dysfunction grading. The patients were retested at the end of treatment. Results: The present study included 39 patients (30 females and 9 males). Best-corrected visual acuity was > 20/30 in >90% of patients in both groups and did not change after treatment. After treatment, improvement in ocular symptoms and meibomian gland dysfunction was more pronounced in group B (p<0.05); the other parameters did not reach statistical significance. Conclusion: Doxycycline improved meibomian gland dysfunction, ocular symptoms, and ocular surface in patients with rosacea. Even though some patients experienced worsening meibomian gland dysfunction and symptoms, no subject experienced any serious complications after administration of low-dose isotretinoin.


RESUMO Objetivos: Comparar o impacto das alterações oculares entre o tratamento sistêmico de doxiciclina e isotretinoína em baixa dosagem em pacientes com rosácea papulopustulosa moderada a grave. Métodos: Os pacientes form randomizados para receber isotretinoína 0,3 a 0,4 mg/kg (grupo A) ou doxiciclina 100mg/dia (grupo B) por 16 semanas. Os sintomas oculares foram pesquisados e avaliados, incluindo melhor acuidade visual corrigida, teste de Schirmer, tempo de ruptura do filme lacrimal, coloração de rosa bengala e graduação da disfunção de glândula de Meibomius. Os pacientes foram novamente testados no final do tratamento. Resultados: O presente estudo incluiu 39 pacientes (30 mulheres e 9 homens). A melhor acuidade visual corrigida foi >20/30 em >90% dos pacientes em ambos os grupos e não se alterou após o tratamento. A melhora dos sintomas oculares e da disfunção de glândula de Meibomius foi mais pronunciada no grupo B (p<0,05) após o tratamento; as demais variáveis não atingiram significância estatística. Conclusão: A doxiciclina melhorou a disfunção de glândula de Meibomius, os sintomas oculares e a superfície ocular de pa cientes com rosácea. Mesmo que alguns pacientes tenham piorado a disfunção e os sintomas da glândula de Meibomius, nenhum indivíduo apresentou complicações graves após a admi nistração de baixas doses de isotretinoína.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Adulto Joven , Isotretinoína/administración & dosificación , Doxiciclina/administración & dosificación , Rosácea/tratamiento farmacológico , Fármacos Dermatológicos/administración & dosificación , Disfunción de la Glándula de Meibomio/tratamiento farmacológico , Antibacterianos/administración & dosificación , Índice de Severidad de la Enfermedad , Agudeza Visual , Administración Oral , Resultado del Tratamiento , Rosácea/fisiopatología , Ojo/efectos de los fármacos , Disfunción de la Glándula de Meibomio/fisiopatología , Glándulas Tarsales/efectos de los fármacos
19.
Drug Deliv ; 27(1): 449-459, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32157918

RESUMEN

Smart phase transformation systems@hard capsule (SPTS@hard capsule) based on lyotropic liquid crystalline (LLC) were developed for oral sustained release in this study. Doxycycline hydrochloride (DOXY) and meloxicam (MLX) were used as hydrophilic and hydrophobic model drug, respectively. Two systems were added with different additives, that is, gelucire 39/01, PEG 1000 and Tween 80 to adjust their melting point and release profiles. The phase transformation of these systems could be triggered by water as well as temperature. They could spontaneously transform into cubic phase or hexagonal phase when coming across with water, to achieve the 24 h sustained release profile. In addition, the obtained systems could switch between semisolid state and liquid state when temperature changed within room temperature and body temperature, which facilitated the phase transformation in gastrointestinal tract and during their encapsulation into hard capsules. LLC-based SPTS@hard capsule revealed potential for the industrialization of its oral administration on account of its drugs accommodation with different solubility, controllable release profile and simple preparation process.


Asunto(s)
Doxiciclina/química , Excipientes/química , Meloxicam/química , Cápsulas , Química Farmacéutica , Preparaciones de Acción Retardada , Doxiciclina/administración & dosificación , Liberación de Fármacos , Glicéridos/química , Interacciones Hidrofóbicas e Hidrofílicas , Cristales Líquidos , Meloxicam/administración & dosificación , Transición de Fase , Polietilenglicoles/química , Polisorbatos/química , Solubilidad , Temperatura , Temperatura de Transición , Agua/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...